--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Travere Therapeutics reached an agreement Tuesday on what data the FDA would require to approve its drug for a kidney disease.

HONOLULU (HawaiiNewsNow) - There’s a new way to monitor how Hawaii is spending $100 million from nationwide opioid lawsuit ...

All four medication safety assessment techniques—incident report review, chart review ... previously hospitalized for medical or surgical treatment at Massachusetts hospitals Postdischarge ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

the good news is that the company has "rarely heard of switching to a competitive drug,” Kitamura said, emphasizing that patients will likely “quickly resume” treatment upon the expected ...

Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

During manic episodes my son enjoyed the sense of optimism that comes from inflated sense of self. He felt that he could ...